Skip to main content
SYBX
OTC Life Sciences

Synlogic, Inc. Declares Itself a 'Public Shell' Following Nasdaq Delisting

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$0.62
Mkt Cap
$7.252M
52W Low
$0.54
52W High
$1.96
52W Position info
15% above low
Off High info
68% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

SYBX is trading near its 52-week low of $0.54 (15% above the low) on light trading volume (0.1× avg).

Summary

Synlogic, Inc. filed an amendment to its delisting 8-K, formally stating its belief that it is a 'public shell' and confirming its shares will trade on the OTCQB Venture Market.


Key Events · Legal and Risk Events · SYBX

  • Public Shell Status Declared

    The company now explicitly states its belief that it is a 'public shell' under Nasdaq rules following its delisting.

  • Transition to OTCQB Venture Market

    Shares are expected to be quoted on the OTCQB Venture Market of OTC Markets Group after delisting from Nasdaq.

  • Delisting Confirmed

    Reaffirms the delisting of its common stock from Nasdaq, effective January 21, 2026, as previously disclosed on January 20, 2026.


Analysis · SYBX · Life Sciences

This amended 8-K provides critical new information by formally stating the company's belief that it is a 'public shell' under Nasdaq rules. This admission, following the recent Nasdaq delisting, significantly reinforces the negative investment thesis, indicating a lack of substantial operations or assets. While the delisting was previously disclosed, the explicit 'public shell' declaration confirms the dire state of the company and suggests a potential path towards liquidation or a reverse merger. The move to the OTCQB Venture Market is a further downgrade in trading venue, reflecting the company's diminished status.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SYBX was trading at $0.62 on OTC in the Life Sciences sector, with a market capitalization of approximately $7.3M. The 52-week trading range was $0.54 to $1.96. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SYBX - Latest Insights

SYBX
Nov 10, 2026, 7:02 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.03
Real-time Price: $0.9602 info
Change: -$0.0698 (-7%) info
Market Cap: $11.761M info
SYBX
Nov 05, 2026, 8:54 AM EST
Filing Type: 425
Importance Score:
7
Price at Filing: $1.00
Real-time Price: $0.9602 info
Change: -$0.0398 (-4%) info
Market Cap: $11.761M info
SYBX
Aug 11, 2026, 4:30 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.18
Real-time Price: $0.9602 info
Change: -$0.2198 (-19%) info
Market Cap: $11.761M info
SYBX
Jul 29, 2026, 7:40 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $1.12
Real-time Price: $0.9602 info
Change: -$0.1598 (-14%) info
Market Cap: $11.761M info
SYBX
Jul 29, 2026, 4:18 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $1.12
Real-time Price: $0.9602 info
Change: -$0.1598 (-14%) info
Market Cap: $11.761M info